• E Tsepkentzi, K Sarafidis, A Sotiriadis, K Chatzistamatiou, and V Drossou-Agakidou.
• 1st Department of Neonatology and Intensive Care Unit, Aristotle University of Thessaloniki, Hippokratio General Hospital, Thessaloniki, Greece.
• Hippokratia. 2016 Jan 1; 20 (1): 73-75.

BackgroundMaternal sartan intake during pregnancy has been associated with several fetal/neonatal complications related to disturbed renal development. Description of cases: We present two cases of neonatal acute kidney injury (AKI) following valsartan administration during pregnancy and provide evidence for the use of novel AKI biomarkers in these neonates. The first case was a female neonate, delivered at 32+4 weeks of gestation after maternal valsartan intake from 24 to 32 gestational weeks. In the second case, ultrasound examination revealed a growth-restricted fetus with severe oligohydramnios following maternal valsartan intake during the first 29 gestational weeks. In the absence of any improvement in amniotic fluid, the neonate was born at 31+5 weeks. In both cases, AKI was documented after birth, but renal function progressively recovered. Urine cystatin-C and neutrophil gelatinase-associated lipocalin were found abnormally increased during the first week of life.ConclusionSartan use during pregnancy is associated with the development of neonatal AKI. Novel urine biomarkers may be used to document renal injury. Hippokratia 2016, 20(1): 73-75.

5 keywords...

hide…